Scinai Immunotherapeutics (NASDAQ:SCNI) Shares to Reverse Split on Thursday, November 19th

Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI)’s stock is set to reverse split before the market opens on Thursday, November 19th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, November 18th.

Scinai Immunotherapeutics Price Performance

Shares of NASDAQ SCNI opened at $0.44 on Friday. Scinai Immunotherapeutics has a 12-month low of $0.39 and a 12-month high of $13.00. The stock has a 50 day simple moving average of $1.28 and a 200-day simple moving average of $4.27. The company has a current ratio of 1.56, a quick ratio of 1.35 and a debt-to-equity ratio of 0.05.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Scinai Immunotherapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) is an Israel-based clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for autoimmune and inflammatory diseases. The company’s research is centered on treatments intended to modulate disease-related immune responses while potentially limiting systemic exposure and associated side effects.

Scinai’s technology platform is based on NanoAb antibody fragments, which are designed to bind specific biological targets and may be suitable for local administration.